WASHINGTON, DC, July 14, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, announced it will hold its annual Cell & Gene Meeting on the Mesa this year on October 5-7, 2016 in La Jolla, California.
This year’s event will attract more than 800 attendees, including senior executives from leading cell therapy, gene therapy and tissue engineering companies worldwide, large pharma and biotech, institutional investors, academic research institutions, patient foundations and disease philanthropies, life science media and more.
“This annual gathering provides the cell and gene therapy community the ideal opportunity to discuss the most pressing issues facing our sector today,” said Robert Preti, Ph.D., president of PCT, Caladrius Biosciences senior vice president, manufacturing and technical operations, and chairman of ARM. “Our sector is poised to continue its upward momentum, and this event provides the ideal forum to discuss the best ways to keep moving forward.”
Organized by ARM and the Sanford Consortium for Regenerative Medicine, this three-day conference features three distinct parts, the program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.
More than 650 participants are expected to attend the event’s sixth annual Partnering Forum on October 5-6, featuring industry executives leading in-depth, interactive panels and workshops to discuss critical commercial, scientific and regulatory issues facing the sector. More than 60 prominent publicly traded and emerging private companies will highlight their clinical and commercial progress to interested partners and investors.
In addition, more than 700 meetings will be scheduled using an online system to connect attendees. This is the largest partnering meeting organized specifically for the cell and gene therapy and regenerative medicine industry, providing the opportunity for participants to establish key relationships and accelerate business development.
The two-day Partnering Forum will conclude on October 6 with the Public Forum and evening reception, held at the Sanford Consortium for Regenerative Medicine. The Public Forum lecture, which is open to the general public and aimed at fostering relationships between the public, industry and academia, will feature a top clinician in the space whose research is poised to become a commercialized product.
The 11th annual Scientific Symposium will take place on October 7 at the Salk Institute for Biological Studies. Attending scientists, clinicians, life science business executives, patient advocates and government officials will examine various near-term scientific and ethical challenges facing cell and gene therapy research today, including panel discussions and keynote presentations from world-renowned researchers. More than 35 posters featuring the latest scientific discoveries will also be on display throughout the day.
Additional event details will be updated regularly on the event website – www.meetingonthemesa.com.
Registration is currently open, with discounted early-bird rates available through August 26. Registration is complimentary for investors and credentialed members of the media. To learn more and to register, please visit www.meetingonthemesa.com. For members of the media interested in attending, please contact ARM’s Senior Director, Communications, Lyndsey Scull at firstname.lastname@example.org.
For interested organizations looking to increase exposure to this field’s top decision-makers via sponsorship, please contact ARM’s Senior Director, Marketing & Events, Laura Parsons at email@example.com for additional information.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
# # #